Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics [Yahoo! Finance]
Acurx Pharmaceuticals, Inc. (ACXP)
Company Research
Source: Yahoo! Finance
Changes in alpha and beta microbiome diversities following IBZ treatment were less pronounced compared to those observed in vancomycin (VAN)-or metronidazole (MET)-treated groups, complementing prior Phase 2 clinical findings showing IBZ's more selective antibacterial activity Notable differences were observed between the microbiome of IBZ- and fidaxomicin (FDX)-treated groups, which may allow for differentiation of these two anti-CDI antibiotics in future studies Results establish IBZ differentiating effects on the gut microbiome, indicating a more selective spectrum of microbiome alteration compared to broader-spectrum antibiotics like VAN and MET and a narrower spectrum of microbiome alteration compared to FDX Preparation continues to advance IBZ into international Ph3 clinical trials for treatment of CDI IBZ has previously been granted FDA QIDP and Fast-Track Designation and has received SME (Small and Medium-sized Enterprise) designation by the EMA STATEN ISLAND, N.Y.
Show less
Read more
Impact Snapshot
Event Time:
ACXP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACXP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACXP alerts
High impacting Acurx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ACXP
News
- Acurx Pharmaceuticals (NASDAQ:ACXP) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ACXP&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx PharmaceuticalsPR Newswire
- New to The Street Airs Landmark Show #700 Today at 6:30 PM ET on Bloomberg Television [Yahoo! Finance]Yahoo! Finance
- Acurx Pharmaceuticals GAAP EPS of -$1.23 beats by $0.05 [Seeking Alpha]Seeking Alpha
- Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business UpdatePR Newswire
ACXP
Earnings
- 11/12/25 - Beat
ACXP
Analyst Actions
- 9/30/25 - HC Wainwright
ACXP
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form 10-Q
- 11/10/25 - Form 424B3
- ACXP's page on the SEC website